IL309317A - Treatment of diseases and disorders associated with MTRES1 - Google Patents
Treatment of diseases and disorders associated with MTRES1Info
- Publication number
- IL309317A IL309317A IL309317A IL30931723A IL309317A IL 309317 A IL309317 A IL 309317A IL 309317 A IL309317 A IL 309317A IL 30931723 A IL30931723 A IL 30931723A IL 309317 A IL309317 A IL 309317A
- Authority
- IL
- Israel
- Prior art keywords
- mtres1
- disorders
- treatment
- related diseases
- diseases
- Prior art date
Links
- 208000037765 diseases and disorders Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163211379P | 2021-06-16 | 2021-06-16 | |
| PCT/US2022/033356 WO2022266045A1 (en) | 2021-06-16 | 2022-06-14 | Treatment of mtres1 related diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309317A true IL309317A (en) | 2024-02-01 |
Family
ID=84527350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309317A IL309317A (en) | 2021-06-16 | 2022-06-14 | Treatment of diseases and disorders associated with MTRES1 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240287518A1 (https=) |
| EP (1) | EP4355878A4 (https=) |
| JP (1) | JP2024523265A (https=) |
| KR (1) | KR20240034185A (https=) |
| CN (1) | CN117980478A (https=) |
| AU (1) | AU2022293669A1 (https=) |
| CA (1) | CA3221625A1 (https=) |
| IL (1) | IL309317A (https=) |
| MX (1) | MX2023015242A (https=) |
| WO (1) | WO2022266045A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024091874A1 (en) * | 2022-10-25 | 2024-05-02 | Empirico Inc. | Gene therapy treatment of mtres1 related diseases and disorders |
| WO2024091873A2 (en) * | 2022-10-25 | 2024-05-02 | Empirico Inc. | Small molecule treatment of mtres1 related diseases and disorders |
| WO2025158407A2 (en) * | 2024-01-26 | 2025-07-31 | Empirico Inc. | Treatment of mtres1 related diseases and disorders |
| WO2025226835A1 (en) * | 2024-04-24 | 2025-10-30 | Empirico Inc. | Gene therapy treatment of mtres1 related diseases and disorders |
| WO2025255269A1 (en) * | 2024-06-05 | 2025-12-11 | Empirico Inc. | Treatment of mtres1 related diseases and disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080279846A1 (en) * | 2007-05-11 | 2008-11-13 | Thomas Jefferson University | Methods of treatment and prevention of neurodegenerative diseases and disorders |
| US10004814B2 (en) * | 2013-11-11 | 2018-06-26 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety |
| US10287580B2 (en) * | 2014-03-14 | 2019-05-14 | The General Hospital Corporation | Molecular re-engineering of excitation-inhibition balance in memory circuits |
| PH12018501207B1 (en) * | 2015-12-21 | 2024-02-23 | Novartis Ag | Compositions and methods for decreasing tau expression |
| EP4004206A1 (en) * | 2019-07-23 | 2022-06-01 | University of Rochester | Targeted rna cleavage with crispr-cas |
-
2022
- 2022-06-14 EP EP22825630.1A patent/EP4355878A4/en active Pending
- 2022-06-14 KR KR1020247000882A patent/KR20240034185A/ko active Pending
- 2022-06-14 US US18/568,758 patent/US20240287518A1/en active Pending
- 2022-06-14 JP JP2023576324A patent/JP2024523265A/ja active Pending
- 2022-06-14 AU AU2022293669A patent/AU2022293669A1/en active Pending
- 2022-06-14 WO PCT/US2022/033356 patent/WO2022266045A1/en not_active Ceased
- 2022-06-14 IL IL309317A patent/IL309317A/en unknown
- 2022-06-14 CA CA3221625A patent/CA3221625A1/en active Pending
- 2022-06-14 CN CN202280056109.XA patent/CN117980478A/zh active Pending
- 2022-06-14 MX MX2023015242A patent/MX2023015242A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024523265A (ja) | 2024-06-28 |
| EP4355878A4 (en) | 2025-04-09 |
| US20240287518A1 (en) | 2024-08-29 |
| KR20240034185A (ko) | 2024-03-13 |
| WO2022266045A1 (en) | 2022-12-22 |
| AU2022293669A1 (en) | 2024-01-18 |
| EP4355878A1 (en) | 2024-04-24 |
| MX2023015242A (es) | 2024-03-11 |
| CN117980478A (zh) | 2024-05-03 |
| CA3221625A1 (en) | 2022-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL309317A (en) | Treatment of diseases and disorders associated with MTRES1 | |
| IL288214A (en) | Quinazolin-4-one derivatives are useful for the treatment of braf-related diseases and disorders | |
| ZA202212876B (en) | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders | |
| EP4090658A4 (en) | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | |
| AU2021381324A9 (en) | Methods of treating diseases and disorders | |
| EP4054713A4 (en) | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING SKIN DISEASES AND DISORDERS USING LEKTI | |
| IL287802A (en) | Preparations and methods for the treatment of eye diseases | |
| IL287748A (en) | Treatment and detection of inherited neuropathies and associated disorders | |
| IL304628A (en) | Treatment of skin disorders | |
| EP4444884A4 (en) | TREATMENT OF FGG-RELATED DISEASES AND DISORDERS | |
| CA3264922A1 (en) | METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS RELATED TO ANGPTL3 | |
| IL321373A (en) | Treatment of mst1-related diseases and disorders | |
| EP4090420A4 (en) | PHOTOTHERAPEUTIC TREATMENT OF SKIN DISEASES | |
| EP4355355A4 (en) | TREATMENT OF PLIN1-ASSOCIATED DISEASES AND DISORDERS | |
| IL309315A (en) | Treatment of mst1 related diseases and disorders | |
| IL321120A (en) | Treatment of mtres1-related diseases and disorders | |
| HK40108572A (en) | Treatment of mtres1 related diseases and disorders | |
| HK40129860A (en) | Treatment of mtres1 related diseases and disorders | |
| CA3274714A1 (en) | Treatment of mtres1 related diseases and disorders | |
| IL280588A (en) | Ophthalmic compositions and methods for treating eye problems and skin diseases | |
| HK40116588A (en) | Treatment of fgg related diseases and disorders | |
| HK40111518A (en) | Treatment of mst1 related diseases and disorders | |
| GB202001353D0 (en) | Treatment of skin conditions | |
| HK40104631A (en) | Treatment of skin disorders | |
| HK40130661A (en) | Treatment of mst1 related diseases and disorders |